Abstract
The addition of a low dose of dopamine (DA) / serotonin1A (5-HT1A) partial agonists, including brexpiprazole (BREX), to selective 5-HT reuptake inhibitors (SSRI) or selective norepinephrine reuptake inhibitors (SNRI), like venlafaxine (VEN) is often used to successfully treat some treatment-resistant major depressive disorder (MDD) patients. Administration of these partial agonists could counterbalance the attenuating actions of SSRIs/SNRIs on firing activity of catecholamine neurons, resulting in reversal of deficient DA and NE tone that could be of crucial importance in the treatment of MDD. This study investigated whether BREX combined with VEN can induce a change in DA neurons activity that is initially not induced by VEN only.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
